Why $CNAT is UP 53% #BeforeBell @ $2.35 ?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Given Consensus Recommendation of "Buy" by Analysts

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has been assigned an average rating of "Buy" from the nine research firms that are presently covering the stock, Market Beat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company.